Plaintiff In Fosamax Bellwether Says Merck Hid Risks

Law360, New York (June 8, 2010, 6:39 PM EDT) -- Merck & Co. has suppressed the development of evidence regarding the health risks associated with Fosamax, a lawyer told jurors Tuesday in the second trial in the case brought by plaintiff Shirley Boles over jaw decay allegedly caused by the osteoperosis drug.

Timothy O’Brien, an attorney for Boles, told jurors in opening statements in the U.S. District Court for the Southern District of New York that he expected Merck to argue that there was “not enough evidence to say Fosamax causes” osteonecrosis of the jaw, or...
To view the full article, register now.